BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26177643)

  • 1. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
    Yee NS
    Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for pancreatic cancer: A long and hopeful journey.
    Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
    Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for pancreatic cancer: current concepts.
    Kaufman HL; Di Vito J; Hörig H
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):159-97, viii. PubMed ID: 12063825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential targets for pancreatic cancer immunotherapeutics.
    Dodson LF; Hawkins WG; Goedegebuure P
    Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic approaches in pancreatic cancer.
    Stieler J
    Recent Results Cancer Res; 2008; 177():165-77. PubMed ID: 18084958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging trends in the immunotherapy of pancreatic cancer.
    Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
    Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for pancreatic cancer: present and future.
    Aroldi F; Zaniboni A
    Immunotherapy; 2017 Jun; 9(7):607-616. PubMed ID: 28595517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current immunotherapeutic strategies in pancreatic cancer.
    Plate JM
    Surg Oncol Clin N Am; 2007 Oct; 16(4):919-43, xi. PubMed ID: 18022552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
    Wu J; Cai J
    Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for pancreatic cancer: A 2020 update.
    Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
    Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in pancreatic cancer: New hope or mission impossible?
    Jiang J; Zhou H; Ni C; Hu X; Mou Y; Huang D; Yang L
    Cancer Lett; 2019 Mar; 445():57-64. PubMed ID: 30641107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
    Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
    Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to relieve immunosuppression in pancreatic cancer.
    Schnurr M; Duewell P; Bauer C; Rothenfusser S; Lauber K; Endres S; Kobold S
    Immunotherapy; 2015; 7(4):363-76. PubMed ID: 25917628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous adenocarcinoma mouse models for immunotherapy.
    Gendler SJ; Mukherjee P
    Trends Mol Med; 2001 Oct; 7(10):471-5. PubMed ID: 11597523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.
    Kimbara S; Kondo S
    World J Gastroenterol; 2016 Sep; 22(33):7440-52. PubMed ID: 27672267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
    Ye C; Zheng L; Yuan CH
    Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies.
    Liu L; Kshirsagar PG; Gautam SK; Gulati M; Wafa EI; Christiansen JC; White BM; Mallapragada SK; Wannemuehler MJ; Kumar S; Solheim JC; Batra SK; Salem AK; Narasimhan B; Jain M
    Theranostics; 2022; 12(3):1030-1060. PubMed ID: 35154473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.
    Hochnadel I; Kossatz-Boehlert U; Jedicke N; Lenzen H; Manns MP; Yevsa T
    Hum Vaccin Immunother; 2017 Dec; 13(12):2931-2952. PubMed ID: 29112462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.